Maxigen Biotech Inc (1783) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Maxigen Biotech Inc stock TWD 45.57, price TWD 35.25, upside +29.3%, quality 81 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 33.75 TWD – 73.84 TWD · fair‑value band 30.53 TWD – 67.14 TWD · the 35.25 TWD price screens below the 45.57 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Maxigen Biotech in your weekly email
Every Wednesday you see whether Maxigen Biotech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products.
Show moreShow less
The company provides biomedical materials, such as collagen and bone supplements; beauty and skincare products; and medical devices for ophthalmology, otolaryngology, dental, surgical, orthopedics, electronic instructions for use, and medical aesthetics, as well as engages in collagen purification activities.
It also offers ophthalmic viscoelastic under the PreviscAid, ViscAid, and BiVisc brands; intra-articular injections under the ArtiBest and ArtiAid brands; synthetic bone grafts under the BestAid, GingivAid, FormaGraft, and Foramic brands; and dermal filler injections under the Formaderm brand.
In addition, the company provides collagen based regenerative matrixes comprising HealiAid, a collagen wound dressing; NasoAid, an intranasal splint; and FormaAid, a collagen membrane. Maxigen Biotech Inc. was incorporated in 1998 and is headquartered in Taoyuan City, Taiwan.
Stock analysis
Maxigen Biotech Inc (1783) currently trades at 35.25 TWD, while our model-based Fair Value estimate is 45.57 TWD, implying the stock looks roughly 23% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 52.29 TWD per share, and 13 of the 26 models we run sit above the 35.25 TWD price.
Bear case: the Asset-Based group reads lowest at 8.54 TWD, and 13 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 30.53 TWD (bear) to 67.14 TWD (bull), the price of 35.25 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 81/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Maxigen Biotech Inc reported revenue of 812M TWD in FY2025 versus 512M TWD in FY2021, a compound +12.2%/yr. Reported net income was 265M TWD in FY2025, compounding +31.9%/yr from FY2021.
Key figures
Market cap 3.1B TWD (≈ $95.6M) Micro · P/E ratio 10.9 · P/S ratio 3.75 · EPS (TTM) 3.23 TWD · Dividend yield 5.7% · Net margin 34.8% · Return on equity 20.0% · Return on assets (EBIT) 11.2% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 81 out of 100 (low confidence).
What moves the price
The share trades about 26% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at 29%, 1783 screens cheaper than that median.
Fair Value models
Bear30.53 TWDFair Value 45.57 TWDBull67.14 TWD
Price 35.25 TWD · Upside +29.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (1.05 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.96/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+19.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.1%
Start year 2020 (pandemic). Over 10 years: +12.0% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+35.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+29.8%
Dividend (yield on the price)5.7%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.17% → 32%
2025 sits 60% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−10.6%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about −11.9% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks
Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score81 · Top 25%
Fair Value upside+29.3% · Top 25%
Profitability
Return on equity (12 months)20.0% · Top 25%
Return on assets14.0% · Top 25%
Net margin (12 months)34.8% · Top 25%
Operating margin (12 months)25.7% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)5.8% · Below median
Dividend yield (12 months)5.7% · Top 25%
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/E (12 months)10.9× · Cheapest 25%
P/B2.04× · Pricier than median
P/S (12 months)3.75× · Pricier than median
Price / free cash flow (fiscal year)15.1× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Maxigen Biotech Inc (1783) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 45.57 TWD versus a price of 35.25 TWD, about +29% upside (undervalued).
What is the fair value of 1783?
Our model-based fair value for Maxigen Biotech Inc is 45.57 TWD (as of Nov 8, 2026), built from audited fundamentals. The current price: 35.25 TWD.
What is the quality score of 1783?
Maxigen Biotech Inc has a Quality Score of 81/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Maxigen Biotech Inc (1783)?
Our model-based price target is the fair value of 45.57 TWD (as of Nov 8, 2026) from 26 valuation models. Cautious scenario 30.53 TWD, optimistic scenario 67.14 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Maxigen Biotech Inc stock forecast for 2026?
Our models put fair value at 45.57 TWD, about +29% upside versus a price of 35.25 TWD (undervalued). Cautious scenario 30.53 TWD, optimistic scenario 67.14 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Maxigen Biotech Inc (1783)?
Maxigen Biotech Inc reported trailing-twelve-month revenue of about 837M TWD (latest available figure, as of Nov 8, 2026).
Does Maxigen Biotech Inc pay a dividend?
Maxigen Biotech Inc currently shows a dividend yield of 5.67% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Maxigen Biotech Inc (1783) and when is the ex-dividend date?
Maxigen Biotech Inc pays a dividend of 2.00 TWD per share a year, a dividend yield of 5.7%. The last ex-dividend date was Sep 1, 2026. The payout ratio is 61.9% of earnings. Free cash flow covers the dividend 1.16 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Maxigen Biotech Inc (1783)?
For today's price to be fair in a discounted-cash-flow model, Maxigen Biotech Inc would have to grow free cash flow by -10.6 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +12.1 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 1783 use?
Our models discount Maxigen Biotech Inc at 11.8 %: a base by market capitalisation (micro), damped by beta 0.36, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Maxigen Biotech Inc that is -10.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Maxigen Biotech Inc (1783) delivered so far?
Over the past 5 years revenue at Maxigen Biotech Inc grew +12.1 % a year. The price currently implies free-cash-flow growth of -10.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Maxigen Biotech Inc (1783) growing?
The median revenue growth in the sector is +3.6 % a year. That is the yardstick for the growth priced into Maxigen Biotech Inc (-10.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Maxigen Biotech Inc (1783)?
The free-cash-flow yield on the price is 10.94 %: that much free cash flow Maxigen Biotech Inc produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Maxigen Biotech Inc (1783)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Maxigen Biotech Inc it is 45.57 TWD per share (as of Nov 8, 2026), against a price of 35.25 TWD. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Maxigen Biotech Inc stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 1783 trades below its calculated fair value: price 35.25 TWD, fair value 45.57 TWD, a gap of about +29% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1783?
No. The price is what the market pays today (35.25 TWD); the fair value is what the company's own numbers justify (45.57 TWD). For Maxigen Biotech Inc the two are 10.32 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Maxigen Biotech Inc worth?
The market values Maxigen Biotech Inc at about 3.1B TWD (market capitalisation, as of Nov 8, 2026). Per share that is 35.25 TWD; our models calculate a fair value of 45.57 TWD per share.
What do the bullish and bearish scenarios say about 1783?
Our models span a range for Maxigen Biotech Inc: cautious scenario 30.53 TWD, base 45.57 TWD, optimistic 67.14 TWD per share (as of Nov 8, 2026, price 35.25 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1783?
Maxigen Biotech Inc trades at a price-to-earnings ratio of 10.9 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 45.57 TWD is built from several models across several years. Other multiples: P/B 2.0, P/S 3.8, EV/EBITDA 8.8.
How solid is the balance sheet of Maxigen Biotech Inc (1783)?
Balance-sheet figures for Maxigen Biotech Inc (as of Nov 8, 2026): return on equity 20.0%. They feed the Quality Score of 81/100, which measures business quality independently of the share price.
How far is 1783 from its 52-week high?
Maxigen Biotech Inc trades at 35.25 TWD, about 26% below its 52-week high of 47.40 TWD and 2% above the low of 34.70 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 45.57 TWD is for.
Which stocks are comparable to Maxigen Biotech Inc?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Maxigen Biotech Inc stock attractive at the current price?
The data as of Nov 8, 2026: price 35.25 TWD, calculated fair value 45.57 TWD (+29%), Quality Score 81/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1783 calculated?
We run Maxigen Biotech Inc through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 45.57 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Maxigen Biotech Inc currently trades 23% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Maxigen Biotech Inc (1783)?
The closing price on Nov 9, 2026 was 35.25 TWD. Our model-based fair value is 45.57 TWD, about +29% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Maxigen Biotech Inc right now?
The rarer combination: high quality (81/100) AND below fair value. That earns a closer look rather than a quick verdict. A fairly wide model range (30.53 TWD to 67.14 TWD) leaves room in how you read the outcome.
Key figures of Maxigen Biotech Inc
How large is the market capitalisation of Maxigen Biotech Inc (1783)?
The market capitalisation of Maxigen Biotech Inc is 3.1B TWD (≈ $95.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Maxigen Biotech Inc (1783)?
The price-to-sales ratio of Maxigen Biotech Inc is 3.75 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Maxigen Biotech Inc (1783)?
Earnings per share at Maxigen Biotech Inc are 3.23 TWD (price ÷ EPS = P/E 10.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Maxigen Biotech Inc (1783)?
The dividend yield of Maxigen Biotech Inc is 5.7% (payout 61.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Maxigen Biotech Inc (1783)?
The net margin of Maxigen Biotech Inc is 34.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Maxigen Biotech Inc (1783)?
The return on equity (ROE) of Maxigen Biotech Inc is 20.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Maxigen Biotech Inc (1783)?
On an EBIT basis the return on assets of Maxigen Biotech Inc is 11.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Maxigen Biotech Inc (1783)?
The operating margin of Maxigen Biotech Inc is 25.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Maxigen Biotech Inc (1783)?
Revenue at Maxigen Biotech Inc is growing +5.8% versus a year earlier (3y avg +10.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Maxigen Biotech Inc (1783)?
Earnings per share at Maxigen Biotech Inc are growing +33.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Maxigen Biotech Inc (1783) hold?
Maxigen Biotech Inc holds more cash than debt, 475M TWD net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Maxigen Biotech Inc in the live analysis
One click puts Maxigen Biotech Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026